Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30228567 | 1.00 | FYN (0.35) | FYNLRRK2GRM4BRD4GAA | |
| SCHEMBL10224611 | 0.95 | LRRK2 (0.35) | FYNLRRK2GRM4 | |
| SCHEMBL883290 | 0.92 | LRRK2 (0.37) | LRRK2GRM4KMT2A | |
| SCHEMBL25256478 | 0.86 | LRRK2 (0.36) | LRRK2 | |
| SCHEMBL25747927 | 0.78 | LRRK2 (0.34) | LRRK2GRM4 | |
| SCHEMBL26632933 | 0.76 | GAA (0.37) | LRRK2GRM4BRD4GAA | |
| SCHEMBL30228553 | 0.73 | — | — | |
| SCHEMBL24168878 | 0.73 | — | — | |
| SCHEMBL876184 | 0.73 | LRRK2 (0.62) | LRRK2 | |
| SCHEMBL13190155 | 0.73 | GAA (0.35) | LRRK2GRM4BRD4GAABRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565497-B2 | Sulfone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20230219953-A1 | SULFONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219953-A1 | SULFONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219953-A1 | SULFONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-07-13 | — | — | US | disclosed |
| CN-115916756-A | Sulfone derivative | 豪夫迈·罗氏有限公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2021259831-A1 | SULFONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-30 | — | — | WO | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-8569281-B2 | Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-29 | — | — | US | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012038743-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-03-29 | — | — | WO | disclosed |
| EP-2408772-A1 | COMPOUNDS | Medical Research Council Technology (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| WO-2010106333-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219953-A1 | SULFONE DERIVATIVES | SULT1E1, SULT1A1, SULT2A1 | FYN 1846/4885LRRK2 2930/4885GRM4 1727/4885 |
| US-20120295883-A1 | COMPOUNDS | ABCC5, PRNP, PC | FYN 317/4885LRRK2 1512/4885GRM4 1526/4885 |
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | FYN 1103/4885LRRK2 2309/4885GRM4 1109/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | FYN 1138/4885LRRK2 2208/4885GRM4 1107/4885 |
| US-12565497-B2 | Sulfone derivatives | CXCR1, CCR1, SULT1E1 | FYN 1594/4885LRRK2 2952/4885GRM4 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.